keyword
MENU ▼
Read by QxMD icon Read
search

Lutetium

keyword
https://www.readbyqxmd.com/read/28471845/early-efficacy-of-and-toxicity-from-lutetium-177-dotatate-treatment-in-patients-with-progressive-metastatic-net
#1
Deborah Pencharz, Martin Walker, Mehmet Yalchin, Ann-Marie Quigley, Martyn Caplin, Christos Toumpanakis, Shaunak Navalkissoor
OBJECTIVE: Lutetium-177 DOTA-D-Phe1-Tyr3-octreotide (Lu-DOTATATE) is a treatment option for patients with well-differentiated metastatic neuroendocrine tumours. Our centre started administering this therapy in 2012. The aim of this study was therefore to analyse the first cohort of patients treated with Lu-DOTATATE to determine its early efficacy and toxicity. PATIENTS AND METHODS: We retrospectively analysed patient, tumour and treatment characteristics, end-of-treatment outcome, time to progression and toxicity in 79 consecutive patients treated with Lu-DOTATATE who had progressive NET according to Response Evaluation Criteria in Solid Tumours criteria...
May 3, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28440324/lutetium-177-labelled-anti-prostate-specific-membrane-antigen-antibody-and-ligands-for-the-treatment-of-metastatic-castrate-resistant-prostate-cancer-a-systematic-review-and-meta-analysis
#2
R J S Calopedos, V Chalasani, R Asher, L Emmett, H H Woo
BACKGROUND: Promising therapeutic results of the prostate-specific membrane antigen (PSMA) ligand have been shown when labelling with lutetium-177 ((177)Lu). We performed a systematic review and meta-analysis to assess the therapeutic response of (177)Lu-PSMA in the treatment of metastatic castration-resistant prostate cancer (mCRPC). METHODS: A systematic review was conducted using electronic databases up to December 2016. Two reviewers independently extracted data and assessed methodological quality...
April 25, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28430624/photosensitizers-in-prostate-cancer-therapy
#3
REVIEW
Taher Gheewala, Troy Skwor, Gnanasekar Munirathinam
The search for new therapeutics for the treatment of prostate cancer is ongoing with a focus on the balance between the harms and benefits of treatment. New therapies are being constantly developed to offer treatments similar to radical therapies, with limited side effects. Photodynamic therapy (PDT) is a promising strategy in delivering focal treatment in primary as well as post radiotherapy prostate cancer. PDT involves activation of a photosensitizer (PS) by appropriate wavelength of light, generating transient levels of reactive oxygen species (ROS)...
May 2, 2017: Oncotarget
https://www.readbyqxmd.com/read/28428192/long-term-efficacy-survival-and-safety-of-177lu-dota0-tyr3-octreotate-in-patients-with-gastroenteropancreatic-and-bronchial-neuroendocrine-tumors
#4
Tessa Brabander, Wouter A Van der Zwan, Jaap Jm Teunissen, Boen L R Kam, Richard A Feelders, Wouter W de Herder, Casper H J van Eijck, Gaston J H Franssen, Eric P Krenning, Dik J Kwekkeboom
Purpose<br /> Bronchial and gastroenteropancreatic neuroendocrine tumors (NETs) are slow-growing tumors, which frequently express somatostatin receptors on their cell membranes. These receptors are targets for therapy with Lutetium-177-labeled somatostatin analogs. We have treated over 1200 patients with peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-DOTATATE) since the year 2000 and present the results on efficacy, survival and toxicity of this therapy. <p>Patients and methods<br /> For safety analysis, 610 patients treated with a cumulative dose of at least 100 mCi (3...
April 20, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28412013/investigation-of-the-imaging-characteristics-of-the-albira-ii-small-animal-pet-system-for-18-f-68-ga-and-64-cu
#5
Ali Asgar Attarwala, Yvonne Wanjiku Karanja, Deni Hardiansyah, Chiara Romanó, Mareike Roscher, Björn Wängler, Gerhard Glatting
AIM: In this study the performance characteristics of the Albira II PET sub-system and the response of the system for the following radionuclides (18)F, (68)Ga and (64)Cu was analyzed. MATERIALS AND METHODS: The Albira II tri-modal system (Bruker BioSpin MRI GmbH, Ettlingen, Germany) is a pre-clinical device for PET, SPECT and CT. The PET sub-system uses single continuous crystal detectors of lutetium yttrium orthosilicate (LYSO). The detector assembly consists of three rings of 8 detector modules...
April 12, 2017: Zeitschrift Für Medizinische Physik
https://www.readbyqxmd.com/read/28398905/an-integrated-model-of-scintillator-reflector-properties-for-advanced-simulations-of-optical-transport
#6
Emilie Roncali, Mariele Stockhoff, Simon R Cherry
Accurately modeling the light transport in scintillation detectors is essential to design new detectors for nuclear medicine or high energy physics. Optical models implemented in software such as Geant4 and GATE suffer from important limitations that we addressed by implementing a new approach in which the crystal reflectance was computed from 3D surface measurements. The reflectance was saved in a look-up-table (LUT) then used in Monte Carlo simulation to determine the fate of optical photons. Our previous work using this approach demonstrated excellent agreement with experimental characterization of crystal light output in a limited configuration, i...
April 11, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28382312/highly-multiplexed-signal-readout-for-a-time-of-flight-positron-emission-tomography-detector-based-on-silicon-photomultipliers
#7
Joshua W Cates, Matthew F Bieniosek, Craig S Levin
Maintaining excellent timing resolution in the generation of silicon photomultiplier (SiPM)-based time-of-flight positron emission tomography (TOF-PET) systems requires a large number of high-speed, high-bandwidth electronic channels and components. To minimize the cost and complexity of a system's back-end architecture and data acquisition, many analog signals are often multiplexed to fewer channels using techniques that encode timing, energy, and position information. With progress in the development SiPMs having lower dark noise, after pulsing, and cross talk along with higher photodetection efficiency, a coincidence timing resolution (CTR) well below 200 ps FWHM is now easily achievable in single pixel, bench-top setups using 20-mm length, lutetium-based inorganic scintillators...
January 2017: Journal of Medical Imaging
https://www.readbyqxmd.com/read/28336867/synthesis-of-multicolor-core-shell-naluf%C3%A2-yb-3-ln-3-caf%C3%A2-upconversion-nanocrystals
#8
Hui Li, Shuwei Hao, Chunhui Yang, Guanying Chen
The ability to synthesize high-quality hierarchical core/shell nanocrystals from an efficient host lattice is important to realize efficacious photon upconversion for applications ranging from bioimaging to solar cells. Here, we describe a strategy to fabricate multicolor core @ shell α-NaLuF₄:Yb(3+)/Ln(3+)@CaF₂ (Ln = Er, Ho, Tm) upconversion nanocrystals (UCNCs) based on the newly established host lattice of sodium lutetium fluoride (NaLuF₄). We exploited the liquid-solid-solution method to synthesize the NaLuF₄ core of pure cubic phase and the thermal decomposition approach to expitaxially grow the calcium fluoride (CaF₂) shell onto the core UCNCs, yielding cubic core/shell nanocrystals with a size of 15...
February 7, 2017: Nanomaterials
https://www.readbyqxmd.com/read/28333041/characterization-of-176-lu-background-in-lso-based-pet-scanners
#9
Maurizio Conti, Lars Eriksson, Harold Rothfuss, Therese Sjoeholm, David Townsend, Göran Rosenqvist, Thomas Carlier
LSO and LYSO are today the most common scintillators used in positron emission tomography. Lutetium contains traces of (176)Lu, a radioactive isotope that decays β (-) with a cascade of γ photons in coincidence. Therefore, Lutetium-based scintillators are characterized by a small natural radiation background. In this paper, we investigate and characterize the (176)Lu radiation background via experiments performed on LSO-based PET scanners. LSO background was measured at different energy windows and different time coincidence windows, and by using shields to alter the original spectrum...
March 23, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28328182/coordination-polymerization-of-renewable-3-methylenecyclopentene-with-rare-earth-metal-precursors
#10
Bo Liu, Shihui Li, Meiyan Wang, Dongmei Cui
Coordination polymerization of renewable 3-methylenecyclopentene has been investigated for the first time using rare-earth metal-based precursors bearing various bulky ligands. All the prepared complexes catalyze controllable polymerization of 3-methylenecyclopentene into high molecular weight polymers, of which the NPN- and NSN-tridentate non-Cp ligated lutetium-based catalytic systems exhibited extremely high activities up to 11 520 kg/(molLu ⋅h) in a dilute toluene solution (3.2 g/100 mL) at room temperature...
March 22, 2017: Angewandte Chemie
https://www.readbyqxmd.com/read/28303694/lutetium-177-psma-radionuclide-therapy-for-men-with-prostate-cancer-a-review-of-the-current-literature-and-discussion-of-practical-aspects-of-therapy
#11
REVIEW
Louise Emmett, Kathy Willowson, John Violet, Jane Shin, Ashley Blanksby, Jonathan Lee
Prostate-specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer cells that is revolutionising the way we image and treat men with prostate cancer. New small molecule peptides with high-binding affinity for the PSMA receptor have allowed high quality, highly specific PET imaging, in addition to the development of targeted radionuclide therapy for men with prostate cancer. This targeted therapy for prostate cancer has, to date, predominately used Lutetium 177 (Lu) labelled PSMA peptides...
March 2017: Journal of Medical Radiation Sciences
https://www.readbyqxmd.com/read/28276897/computational-modeling-of-radiobiological-effects-in-bone-metastases-for-different-radionuclides
#12
Francisco D C Guerra Liberal, Adriana Alexandre S Tavares, João Manuel R S Tavares
PURPOSE: Computational simulation is a simple and practical way to study and to compare a variety of radioisotopes for different medical applications, including the palliative treatment of bone metastases. This study aimed to evaluate and compare cellular effects modelled for different radioisotopes currently in use or under research for treatment of bone metastases using computational methods. METHODS: Computational models were used to estimate the radiation-induced cellular effects (Virtual Cell Radiobiology algorithm) post-irradiation with selected particles emitted by Strontium-89 ((89)Sr), Samarium-153 ((153)Sm), Lutetium-177 ((177)Lu), and Radium-223 ((223)Ra)...
March 3, 2017: International Journal of Radiation Biology
https://www.readbyqxmd.com/read/28263217/peptide-receptor-radionuclide-therapy-with-177lu-octreotate-in-patients-with-somatostatin-receptor-expressing-neuroendocrine-tumors-six-years-assessment
#13
Mohammadali Hamiditabar, Muzammil Ali, Joseph Roys, Edward M Wolin, Thomas M OʼDorisio, David Ranganathan, Izabela Tworowska, Jonathan R Strosberg, Ebrahim S Delpassand
OBJECTIVES: Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues is a promising treatment for patients with inoperable, well to moderately differentiated metastatic neuroendocrine tumors (NETs). In continuation of our novel study with the radionuclide lutetium Lu, we now present further results of Lu DOTATATE therapy in managing NETs and other somatostatin receptor-expressing tumors in a larger and more diverse patient group. PATIENTS AND METHODS: One hundred forty-four consecutive patients (85 men and 59 women; age range, 11-87 years; mean age, 58...
June 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28262415/recycling-and-separation-of-rare-earth-resources-lutetium-from-lyso-scraps-using-the-diglycol-amic-acid-functional-xad-type-resin
#14
Peng Chen, Fan Yang, Qiuxia Liao, Zhigang Zhao, Yang Zhang, Panpan Zhao, Wanghuan Guo, Ruixi Bai
No abstract text is available yet for this article.
March 2, 2017: Waste Management
https://www.readbyqxmd.com/read/28211032/depth-of-interaction-determination-in-monolithic-scintillator-with-double-side-sipm-readout
#15
Matteo Morrocchi, Giovanni Ambrosi, Maria Giuseppina Bisogni, Filippo Bosi, Marco Boretto, Piergiorgio Cerello, Maria Ionica, Ben Liu, Francesco Pennazio, Maria Antonietta Piliero, Giovanni Pirrone, Vasile Postolache, Richard Wheadon, Alberto Del Guerra
BACKGROUND: Monolithic scintillators read out by arrays of photodetectors represent a promising solution to obtain high spatial resolution and the depth of interaction (DOI) of the annihilation photon. We have recently investigated a detector geometry composed of a monolithic scintillator readout on two sides by silicon photomultiplier (SiPM) arrays, and we have proposed two parameters for the DOI determination: the difference in the number of triggered SiPMs on the two sides of the detector and the difference in the maximum collected signal on a single SiPM on each side...
December 2017: EJNMMI Physics
https://www.readbyqxmd.com/read/28182580/internal-dosimetry-with-the-monte-carlo-code-gate-validation-using-the-icrp-icru-female-reference-computational-model
#16
Daphnée Villoing, Sara Marcatili, Marie-Paule Garcia, Manuel Bardiès
The purpose of this work was to validate GATE-based clinical scale absorbed dose calculations in nuclear medicine dosimetry. GATE (version 6.2) and MCNPX (version 2.7.a) were used to derive dosimetric parameters (absorbed fractions, specific absorbed fractions and S-values) for the reference female computational model proposed by the International Commission on Radiological Protection in ICRP report 110. Monoenergetic photons and electrons (from 50 keV to 2 MeV) and four isotopes currently used in nuclear medicine (fluorine-18, lutetium-177, iodine-131 and yttrium-90) were investigated...
March 7, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28113455/design-features-and-mutual-compatibility-studies-of-the-time-of-flight-pet-capable-ge-signa-pet-mr-system
#17
Craig S Levin, Sri Harsha Maramraju, Mohammad Mehdi Khalighi, Timothy W Deller, Gaspar Delso, Floris Jansen
A recent entry into the rapidly evolving field of integrated PET/MR scanners is presented in this paper: a whole body hybrid PET/MR system (SIGNA PET/MR, GE Healthcare) capable of simultaneous acquisition of both time-of-flight (TOF) PET and high resolution MR data. The PET ring was integrated into an existing 3T MR system resulting in a (patient) bore opening of 60 cm diameter, with a 25 cm axial FOV. The PET ring is placed between the shielded RF body coil and the gradient coils. The PET detectors are based on silicon photomultipliers coupled to lutetium based scintillators...
March 9, 2016: IEEE Transactions on Medical Imaging
https://www.readbyqxmd.com/read/28111101/design-of-a-new-tracking-device-for-on-line-beam-range-monitor-in-carbon-therapy
#18
Giacomo Traini, Giuseppe Battistoni, Angela Bollella, Francesco Collamati, Erika De Lucia, Riccardo Faccini, Fernando Ferroni, Paola Maria Frallicciardi, Carlo Mancini-Terracciano, Michela Marafini, Ilaria Mattei, Federico Miraglia, Silvia Muraro, Riccardo Paramatti, Luca Piersanti, Davide Pinci, Antoni Rucinski, Andrea Russomando, Alessio Sarti, Adalberto Sciubba, Martina Senzacqua, Elena Solfaroli-Camillocci, Marco Toppi, Cecilia Voena, Vincenzo Patera
Charged particle therapy is a technique for cancer treatment that exploits hadron beams, mostly protons and carbon ions. A critical issue is the monitoring of the beam range so to check the correct dose deposition to the tumor and surrounding tissues. The design of a new tracking device for beam range real-time monitoring in pencil beam carbon ion therapy is presented. The proposed device tracks secondary charged particles produced by beam interactions in the patient tissue and exploits the correlation of the charged particle emission profile with the spatial dose deposition and the Bragg peak position...
February 2017: Physica Medica: PM
https://www.readbyqxmd.com/read/28076709/phase-3-trial-of-177-lu-dotatate-for-midgut-neuroendocrine-tumors
#19
RANDOMIZED CONTROLLED TRIAL
Jonathan Strosberg, Ghassan El-Haddad, Edward Wolin, Andrew Hendifar, James Yao, Beth Chasen, Erik Mittra, Pamela L Kunz, Matthew H Kulke, Heather Jacene, David Bushnell, Thomas M O'Dorisio, Richard P Baum, Harshad R Kulkarni, Martyn Caplin, Rachida Lebtahi, Timothy Hobday, Ebrahim Delpassand, Eric Van Cutsem, Al Benson, Rajaventhan Srirajaskanthan, Marianne Pavel, Jaime Mora, Jordan Berlin, Enrique Grande, Nicholas Reed, Ettore Seregni, Kjell Öberg, Maribel Lopera Sierra, Paola Santoro, Thomas Thevenet, Jack L Erion, Philippe Ruszniewski, Dik Kwekkeboom, Eric Krenning
BACKGROUND: Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 ((177)Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. METHODS: We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either (177)Lu-Dotatate (116 patients) at a dose of 7...
January 12, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28059121/structural-effects-of-lanthanide-dopants-on-alumina
#20
Ketan Patel, Victoria Blair, Justin Douglas, Qilin Dai, Yaohua Liu, Shenqiang Ren, Raymond Brennan
Lanthanide (Ln(3+)) doping in alumina has shown great promise for stabilizing and promoting desirable phase formation to achieve optimized physical and chemical properties. However, doping alumina with Ln elements is generally accompanied by formation of new phases (i.e. LnAlO3, Ln2O3), and therefore inclusion of Ln-doping mechanisms for phase stabilization of the alumina lattice is indispensable. In this study, Ln-doping (400 ppm) of the alumina lattice crucially delays the onset of phase transformation and enables phase population control, which is achieved without the formation of new phases...
January 6, 2017: Scientific Reports
keyword
keyword
6841
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"